Abstracts tagged "meta-analysis and osteoarthritis"

Abstract Number: 1304 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Hylan G-F 20 versus Intra-Articular Corticosteroids in Patients with Knee Osteoarthritis: A Systematic Literature Review, Meta-Analysis, and Network Meta-analysis
Xavier Chevalier ¹, Brendan Sheehan ², Craig Whittington ³, Chunyi Ho ⁴, Wilson Ngai⁵ and Gustavo Campos ⁶, ¹Department of Rheumatology, Hospital henri Mondor, Paris University XII, Creteil, France, ²Department of Medicine, Dalhousie University, Saint John, NB, Canada, ³Doctor Evidence, Santa Monica, CA, ⁴Doctor Evidence, Santa Monica, ⁵Sanofi, U.S. Medical Affairs, Bridgewater, ⁶Universidade Estadual de Campinas, Campinas, Brazil
Background/Purpose: Knee OA is a progressive joint disease which affects more than 250 million people worldwide. Meta-analysis (MA) has demonstrated that IA CS were more…
Abstract Number: 1200 • 2017 ACR/ARHP Annual Meeting
Updating the Knee Osteoarthritis Intra-Articular Corticosteroid Meta-Analysis with Two Large Trials of Extended-Release Triamcinolone Acetonide (FX006) Versus Placebo
Philip G. Conaghan¹, Francis Berenbaum², Virginia B. Kraus³, James Johnson⁴ and Scott Kelley⁵, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²Pierre & Marie Curie University, Saint-Antoine Hospital, Paris, France, ³Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC, ⁴Summit Analytical, Denver, CO, ⁵Flexion Therapeutics, Inc., Burlington, MA
Background/Purpose: A recent meta-analysis concluded that intra-articular corticosteroids (IACS) for knee osteoarthritis (OA) may be associated with moderate improvement in pain compared with control treatment.1,2…
Abstract Number: 293 • 2016 ACR/ARHP Annual Meeting
A Systematic Review and Network Meta-Analysis of Long-Term Trials of Pharmacological Treatments in Knee Osteoarthritis
Dario Gregori¹, Giampaolo Giacovelli², Clara Minto¹, Beatrice Barbetta², Francesca Gualtieri², Danila Azzolina¹, Paola Vaghi² and Lucio C. Rovati^2,3, ¹Unit of Biostatistics, Epidemiology and Public Health, Department of Cardiac, Thoracic and Vascular Sciences, University of Padova, Padova, Italy, ²Clinical Research Department, Rottapharm Biotech, Monza, Italy, ³University of Milano Bicocca, Milano, Italy
Background/Purpose: Osteoarthritis (OA) is a chronic and progressive degenerative disease. While management of OA should be directed to long-term control of symptoms and joint structure…
Abstract Number: 986 • 2012 ACR/ARHP Annual Meeting
Genome Wide Association Studies of Knee Osteoarthritis in 2 Large North American Cohorts: A Meta-Analysis with 2667 Cases
Marc C. Hochberg¹, Laura Yerges-Armstrong², Changwan (Larry) Lu³, Michelle S. Yau⁴, Braxton D. Mitchell², Joanne M. Jordan⁵, Youfang Liu⁶, Jordan B. Renner⁷, T. McSherry⁸, D.M. Taverna⁸, David Duggan⁹, W.J. Mysiw¹⁰ and Rebecca D. Jackson¹⁰, ¹Department of Medicine, University of Maryland, Baltimore, MD, ²Departments of Medicine and Epidemiology & Public Health, University of Maryland School of Medicine, Baltimore, MD, ³University of Maryland School of Medicine, Baltimore, MD, ⁴University of Maryland, Baltimore, MD, ⁵Thurston Arthritis Research Center, University of North Carolina, Chapel Hill, NC, ⁶University of North Carolina, Chapel Hill, NC, ⁷University of North Carolina Department of Radiology, Chapel Hill, NC, ⁸TGen, Pheonix, AZ, ⁹Translational Genomics Research Institute, Phoenix, AZ, ¹⁰Ohio State University, Columbus, OH
Background/Purpose: A strong genetic contribution to knee osteoarthritis (OA) is widely recognized although few loci have been robustly associated with knee OA susceptibility. To identify…
Abstract Number: 257 • 2012 ACR/ARHP Annual Meeting
Meta-Analysis of Four 12-Week Phase III Clinical Trials Investigating the Effect of TDT 064, a Transdermal Gel, in Osteoarthritis of the Knee
Matthias Rother¹, Johannes C. Vester², Wolfgang W. Bolten³ and Philip G. Conaghan⁴, ¹IMR Partner GmbH, Graefelfing, Germany, ²IDV Data Analysis and Study Planning, Krailling, Germany, ³Rheumatology, Klaus-Miehlke-Klink, Wiesbaden, Germany, ⁴University of Leeds, Leeds, United Kingdom
Background/Purpose: A transfersome is an ultradeformable lipid vesicle originally developed to deliver high concentrations of drug (eg NSAIDs) transdermally. Large interventional trials in osteoarthritis (OA)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].